Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) Strengthening IP Portfolio Affirm Long Term Prospects

Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) impressive start to the year is at risk. The stock has pulled lower from one-year highs in what appears to be a corrective phase. A 20% pullback comes, even on the company strengthening its intellectual patent portfolio.

Cure Price Analysis

The pharmaceutical company is fresh from securing a new patent that details the high loading of the active ingredient in oral thin films. In addition, the company has also secured a patent on oral thin films with Biphasic release of natural ingredients. The announcement of a strategic partnership with Canopy Growth Corp (NYSE:CGC) also went a long way in strengthening the stock’s sentiments in the market prior to the pullback.

The stock’s short-term momentum has turned bearish in recent weeks as short sellers continue to take the fight to the bulls. As the stock continues to trade in a downtrend with a bearish bias, immediate support as part of the correction phase is seen at the $3.20 level.

A sell-off followed by a close below the $3.20 level could give short sellers a reason to continue pushing CURE Pharmaceutical lower. Conversely, the stock stabilizing above the $3.20 level could trigger a bounce-back likely to support further upside action, in continuation of the long-term uptrend.

Strengthening IP Portfolio

Amidst the recent price action activity, CURE Pharmaceutical remains bullish as a long-term play. The strengthening of the patent portfolio should continue to strengthen investors sentiments in the stock.

The new patent on oral thin films with Bi-Phasic release should go along way in expanding the pharmaceutical company’s proprietary drug system CURE film. The patent on high loading of the active ingredient in oral thin films should also enhance the company’s ability to come up with thin edible films that can deliver high doses. The new patents also pave the way for the pharmaceutical company to differentiate its oral thin films for specific drug opportunities such as cannabidiol.

“With an increased consumer demand for natural wellness products, one of our areas of focus is to improve the delivery plant components and extracts in novel ways. With this patent, we continue to build out our capabilities and IP portfolio around Phyto-actives,” explained CEO Rob Davidson.

By Steven Russell

Steve covers business and investing in emerging medical marijuana markets. Steve graduated from the university of New Orleans with a degree in Broadcast Journalism. Steve has published several articles in professional journals and magazines. His experience gives readers an inside look at the intersection of his specialties, business and medical marijuana.

Leave a Reply

Your email address will not be published. Required fields are marked *

Pin It on Pinterest